Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $24.25.

Several research firms recently commented on XNCR. JPMorgan Chase & Co. raised their target price on Xencor from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Monday, May 11th. Truist Financial decreased their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Wall Street Zen lowered Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Zacks Research raised shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a report on Wednesday, June 24th.

Institutional Trading of Xencor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Xencor during the fourth quarter valued at $81,000. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares during the period. E Fund Management Co. Ltd. purchased a new stake in shares of Xencor during the 2nd quarter worth about $79,000. NorthCrest Asset Manangement LLC purchased a new stake in shares of Xencor during the 4th quarter worth about $149,000. Finally, Norges Bank purchased a new stake in shares of Xencor during the 4th quarter worth about $175,000.

Xencor Stock Performance

Shares of XNCR opened at $15.85 on Monday. The business’s 50-day moving average is $12.92 and its two-hundred day moving average is $12.77. The company has a market capitalization of $1.18 billion, a P/E ratio of -6.92 and a beta of 0.86. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $18.69.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The business’s quarterly revenue was down 86.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.66) EPS. Analysts forecast that Xencor will post -3.88 EPS for the current year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.